Promising Shionogi Candidate Moves Ahead In Gram-Negative Pneumonia
Executive Summary
Novel Shionogi antibiotic candidate set to move ahead following positive results in Gram-negative pneumonia, where resistance and unmet needs remain critical factors.
You may also be interested in...
Evotec Takes The Lead On EU-Backed Antibiotic R&D Project
The 11-member GNA NOW alliance aims to move a treatment for some of the most threatening drug-resistant bacteria through early-phase development by 2024 using a mix of public and private funds.
Keeping Track: Recarbrio Approval Highlights Two-Week Roundup
The latest drug development news and highlights for our US FDA Performance Tracker.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.